Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Lung cancer has traditionally been associated with advanced age; however, its increasing incidence among young adults raises concerning questions regarding its etiology and unique considerations for ...

Effective treatment options, such as resection, liver transplantation, and ablation, exist for early-stage HCC, and patients with locally advanced disease may be candidates for liver-directed ...

Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD (L)1 ...

Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All ...

The purpose of this guideline is to update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. ASCO first published a practice ...

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor ...

Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...

In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement ...

Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly (ADP-ribose) polymerase inhibitors, ...

This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by TP53 aberration (ClinicalTrials.gov identifier: NCT03580928).

Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized ...